National Health Act 1953 Amendment determination under section 85B price determinations and special patient contributions (No. PB 33 of 2008) (Cth)

Case
No judgment structure available for this case.

Amendment — price determinations and special patient contributions
(PB 33 of 2008)

as amended

made under section 85B of the

National Health Act 1953

This compilation was prepared on 1 April 2008
taking into account amendments up to PB 40 of 2008

Prepared by the Office of Legislative Drafting and Publishing,
Attorney-General’s Department, Canberra

Amendment — price determinations and special patient contributions

(PB 33 of 2008)

1              Commencement

This instrument commences on 1 April 2008.

2              Amendment of PB 91 of 2007

Schedule 1 amends PB 91 of 2007.

Schedule 1        Amendments

[1]           Schedule 1, item dealing with Alendronic Acid

(b) omit from the column headed “Claimed Price”:

37.77

and substitute:

38.57

[2]           Schedule 1, item dealing with Brinzolamide

(a) omit from the column headed “Determined Price”:

12.93

and substitute:

13.56

(b) omit from the column headed “Claimed Price”:

13.82

and substitute:

14.47

[3]           Schedule 1, item dealing with Ciprofloxacin in the form Eye drops 3 mg (as hydrochloride) per mL, 5 mL

(a) omit from the column headed “Determined Price”:

11.18

and substitute:

11.54

(b) omit from the column headed “Claimed Price”:

12.26

and substitute:

12.61

[4]           Schedule 1, item dealing with Diphenoxylate with Atropine

(a) omit from the column headed “Determined Price”:

1.71

and substitute:

1.95

(b) omit from the column headed “Claimed Price”:

3.33

and substitute:

3.57

[5]           Schedule 1, item dealing with Flucloxacillin

omit from the columns in the order indicated:

Powder for oral suspension 250 mg (as magnesium) per 5 mL, 100 mL Oral Floxapen 1 8.53 8.61

[6]           Schedule 1, item dealing with Gemfibrozil

(a) omit from the column headed “Determined Price”:

30.83

and substitute:

26.98

(b) omit from the column headed “Claimed Price”:

33.90

and substitute:

29.66

[7]           Schedule 1, item dealing with Loperamide

(a) omit from the column headed “Determined Price”:

1.71

and substitute:

1.93

(b) omit from the column headed “Claimed Price”:

2.53

and substitute:

2.75

[8]           Schedule 1, items dealing with Nizatidine in the forms Capsule 150 mg and Capsule 300 mg

(a) omit from the column headed “Determined Price”:

16.33

and substitute:

14.65

[9]           Schedule 1, omit item dealing with Pemetrexed

[10]         Schedule 1, item dealing with Potassium Chloride

(a) omit from the column headed “Determined Price”:

2.77

and substitute:

3.05

(b) omit from the column headed “Claimed Price”:

4.03

and substitute:

4.30

[11]         Schedule 1, item dealing with Potassium Chloride with Potassium Bicarbonate

(a) omit from the column headed “Determined Price”:

5.53

and substitute:

5.90

(b) omit from the column headed “Claimed Price”:

7.84

and substitute:

8.21

[12]         Schedule 1, item dealing with Prednisolone in the form Tablet 1 mg

(a) omit from the column headed “Determined Price”:

2.24

and substitute:

2.33

(b) omit from the column headed “Claimed Price”:

2.78

and substitute:

2.87

[13]         Schedule 1, item dealing with Prednisolone in the form Oral solution 5 mg (as sodium phosphate) per mL, 30 mL

(a) omit from the column headed “Determined Price”:

7.33

and substitute:

7.58

(b) omit from the column headed “Claimed Price”:

8.95

and substitute:

9.20

[14]         Schedule 1, item dealing with Prednisone

(a) omit from the column headed “Determined Price”:

2.24

and substitute:

2.29

(b) omit from the column headed “Claimed Price”:

2.78

and substitute:

2.87

[15]         Schedule 1, item dealing with Quinine

(a) omit from the column headed “Determined Price”:

5.02

and substitute:

5.35

(b) omit from the column headed “Claimed Price”:

6.95

and substitute:

7.28

[16]         Schedule 1, item dealing with Salbutamol in the form Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30

(a) omit from the column headed “Determined Price”:

8.29

and substitute:

7.25

(b) omit from the column headed “Claimed Price”:

9.26

and substitute:

8.10

[17]         Schedule 1, item dealing with Salbutamol in the form Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30

(a) omit from the column headed “Determined Price”:

8.76

and substitute:

7.67

(b) omit from the column headed “Claimed Price”:

9.73

and substitute:

8.51

[18]         Schedule 1, item dealing with Simvastatin in the form Tablet 5 mg

omit from the column headed “Claimed Price”:

16.29

and substitute:

16.86

[19]         Schedule 1, item dealing with Simvastatin in the form Tablet 10 mg (Lipex 10 and Zocor)

omit from the column headed “Claimed Price”:

22.27

and substitute:

22.84

[20]         Schedule 1, item dealing with Simvastatin in the form Tablet 20 mg (Lipex 20 and Zocor)

omit from the column headed “Claimed Price”:

31.73

and substitute:

32.30

[21]         Schedule 1, item dealing with Simvastatin in the form Tablet 40 mg (Lipex 40 and Zocor)

omit from the column headed “Claimed Price”:

45.37

and substitute:

45.95

[22]         Schedule 1, item dealing with Simvastatin in the form Tablet 80 mg (Lipex 80 and Zocor)

omit from the column headed “Claimed Price”:

64.94

and substitute:

65.51

[23]         Schedule 1, item dealing with Thyroxine in the form Tablet containing 50 micrograms anhydrous thyroxine sodium

(a) omit from the column headed “Determined Price”:

13.52

and substitute:

15.98

(b) omit from the column headed “Claimed Price”:

14.67

and substitute:

17.13

[24]         Schedule 1, item dealing with Thyroxine in the form Tablet containing 100 micrograms anhydrous thyroxine sodium

(a) omit from the column headed “Determined Price”:

14.47

and substitute:

16.55

(b) omit from the column headed “Claimed Price”:

15.63

and substitute:

17.71

[25]         Schedule 1, item dealing with Thyroxine in the form Tablet containing 200 micrograms anhydrous thyroxine sodium

(a) omit from the column headed “Determined Price”:

19.21

and substitute:

19.41

(b) omit from the column headed “Claimed Price”:

20.35

and substitute:

20.55

[26]         Schedule 1, item dealing with Timolol in the form Eye drops 2.5 mg (as maleate) per mL, 5 mL

omit from the column headed “Claimed Price”:

7.19

and substitute:

7.60

[27]         Schedule 1, item dealing with Timolol in the form Eye drops 5 mg (as maleate) per mL, 5 mL

omit from the column headed “Claimed Price”:

8.19

and substitute:

8.55

[28]         Schedule 1, item dealing with Tramadol in the form Capsule containing tramadol hydrochloride 50 mg

omit from the column headed “Claimed Price”:

4.49

and substitute:

5.99

[29]         Schedule 1, item dealing with Tramadol in the form Tablet containing tramadol hydrochloride 100 mg (sustained release)

omit from the column headed “Claimed Price”:

10.39

and substitute:

13.85

[30]         Schedule 1, item dealing with Tramadol in the form Tablet containing tramadol hydrochloride 150 mg (sustained release)

omit from the column headed “Claimed Price”:

13.39

and substitute:

17.85

[31]         Schedule 1, item dealing with Tramadol in the form Tablet containing tramadol hydrochloride 200 mg (sustained release)

omit from the column headed “Claimed Price”:

15.91

and substitute:

21.21

[32]         Schedule 1, item dealing with Triamcinolone with Neomycin, Gramicidin and Nystatin in the form Ear drops containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 7.5 mL

(a) omit from the column headed “Determined Price”:

2.08

and substitute:

4.40

(b) omit from the column headed “Claimed Price”:

3.04

and substitute:

5.35

[33]         Schedule 2, omit item dealing with Pemetrexed

Notes to the Amendment — price determinations and special patient contributions (PB 33 of 2008)

Note 1

The Amendment — price determinations and special patient contributions (PB 33 of 2008) (in force under section 85B of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.

Table of Instruments

Title

Date of FRLI Registration

Date of
commencement

Application, saving or
transitional provisions

PB 33 of 2008 11 Mar 2008 (see F2008L00698) 1 Apr 2008
PB 40 of 2008 26 Mar 2008 (see F208L00958) (a)

(a)    Section 1 of PB 40 of 2008 provides as follows:

1.   Commencement

This instrument commences at 8 pm on 31 March 2008.

Table of Amendments

ad. = added or inserted      am. = amended      rep. = repealed      rs. = repealed and substituted

Provision affected

How affected

Schedule 1
Schedule 1............................. am. PB 40 of 2008
Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0